From Best of 2021 ASH to 2022 COVID-19 Guidance
IMF Patient and Family Webinar
Learn how to better manage side effects, discover optimal choices for relapsed patients, receive updates on ASH 2021 and 2022 COVID-19 Guidance, gather information about CAR T-cell therapies, and more. IMF Chairman of the Board Dr. Brian G.M. Durie moderates presentations by Dr. Thomas Martin (University of California — San Francisco, CA), Dr. Saad Usmani (Memorial Sloan Kettering Cancer Center — New York, NY), and Donna Catamero, ANP-BC, OCN, CCRC of the IMF Nurse Leadership Board (Ichan School of Medicine at Mount Sinai Hospital — New York, NY).
What to Expect
Dr. Durie will kick off the webinar with a review of Myeloma 101. He will discuss MGUS, smoldering myeloma, and active myeloma, and address when patients may consider beginning treatment. He will also cover tests for diagnosis and monitoring, as well as how the disease is staged, and more.
Next, IMF Nurse Leadership Board Member Donna Catamero ANP-BC, OCN, CCRC (Mount Sinai Health System, IMF Nurse Leadership Board) will present Side Effects and Symptom Management and discuss how patients can best manage myeloma-related symptoms and side effects, as well as side effects brought on by treatment. She outlines the most common side effects for each myeloma drug category, and more.
In his segment, Best of ASH 2021 to 2022 COVID-19 Guidance, Dr. Durie will share updates from the top myeloma-related abstracts from the 2021 American Society of Hematology (ASH) meeting and provide the latest COVID-19 guidance and recommendations for patients in 2022.
In this presentation on the Evolving Role of Immune Therapies: A Focus on CAR T-cell Therapies, Dr. Thomas Martin (University of California — San Francisco) will discuss the remarkable progress being made in the treatment of multiple myeloma using immune therapies, with a specific focus on CAR T-cell therapies. He will detail what CAR T-cell therapy is and how this type of therapy uses a patient's own immune system to target myeloma. Dr. Martin will also outline other emerging immune therapies on the horizon.
Saad Usmani, MD (Memorial Sloan Kettering Cancer Center) will talk about Approaches to Relapse. He will cover how patients should treat relapsed disease, the current bispecifics and novel agents available, and practical approaches to relapse.
You won’t want to miss this lively webinar. At the end of the presentations, participants will have time to ask questions.
If you miss the webinar, a replay will be available afterwards, with participants' questions at the end.
Acquaint yourselves with the following resources on the IMF website to better understand the discussions.
*Of note, Venetoclax has already been approved to treat acute myeloid leukemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults and is now being evaluated to treat other types of cancers, including multiple myeloma. It is part of a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors that work by blocking the action of BCL-2 (a protein in the body that regulates cell death). Trials using Venetoclax were discussed in this webinar. You can learn about these three trials at the following links:
- CANOVA Clinical Trial Fact Sheet
clinicaltrials.gov Identifier: NCT03539744
- Phase II Relapsed or Refractory Venetoclax Trial
clinicaltrials.gov Identifier: NCT02899052
- Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib
clinicaltrials.gov Identifier: NCT03314181
Watch Ask Dr. Durie Videos:
Download the IMF's Multiple Myeloma Informational Booklets:
Patient and Family Webinar Sponsors:
with support from:
Amgen, Bristol Myers Squibb, Genentech, GSK, Janssen, and Takeda Oncology
Please check out these multiple myeloma resources from our sponsors:
|Even The Odds|